What changed from existing technology?
This study used computer models to find harmful changes in the CDKN1B gene that affect a protein important for stopping cancer growth. It found one specific change that makes the protein less stable and others that might affect how the gene works.
This study is the first to comprehensively analyze both coding and non-coding variants in CDKN1B using multiple computational approaches to predict their functional impact and regulatory effects.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
n of both coding and non-coding variants in this gene remains limited. This study presents an integrated computational investigation of deleterious codin
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
- 시뮬레이션·이론 중심이며 물리적 검증 근거가 확인되지 않음
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This computational approach could help identify disease-associated variants in CDKN1B that may contribute to cancer development and inform targeted therapeutic strategies.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.